Development of user-friendly consumer and health professional resources for the antipsychotic clozapine: a New Zealand example
File version
Author(s)
Miles, SW
Wheeler, AJ
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
The antipsychotic clozapine has been shown to have superior efficacy to most other treatments for psychosis, especially where treatment-resistant schizophrenia has been diagnosed. Like all medications, clozapine has a number of well-recognised adverse effects, some of which can be fatal. Evidence also suggests that those for whom clozapine is the most suitable treatment option do not receive it because the doctor or health system views the risks as too great to prescribe. The provision of guidelines including innovative consumer and general practitioner resources regarding the ways to most safely monitor and manage people who are exposed to clozapine has the potential to increase the safe use of the product and also to provide potential prescribers with more confidence in using it. This paper outlines both the process for development and the final package produced by a large metropolitan District Health Board service in Auckland, New Zealand. This material was aimed at non-specialist prescribers as well as consumers and their family/carers and other supports.
Journal Title
BMJ Innovations
Conference Title
Book Title
Edition
Volume
1
Issue
1
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Public Health and Health Services not elsewhere classified